Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Accelerating synthetic chemistry with a predictive retrosynthesis solution
Posted on August 12th, 2021 by Ann-Marie Roche in AI & Data
In most aspects of life, we think of “endless possibilities” as a good thing. But in science, the wealth of possibilities can be daunting. Pharmaceutical researchers typically start with a disease that they want to tackle, find a target, and then try to identify compounds which interact with that target. There may be around 200-300 drug candidates per project, and synthesis planning and execution usually takes four to eight weeks per drug candidate. This process requires many chemists and a huge, costly effort to proceed.
(more…)Confronting the Problem of AI Bias
Posted on June 18th, 2021 by Ann-Marie Roche in AI & Data
When thinking of artificial intelligence (AI), many people rely on cultural touchstones from science fiction films and TV. They might think of HAL, the calm-voiced AI from 2001: A Space Odyssey, or Data, the even-tempered android from Star Trek. We tend to imagine that artificial intelligence will be driven by reason, logic and facts – not by the emotions and prejudices that get us regular humans into trouble so often.
(more…)FDA Introduces Data Modernization Action Plan
Posted on March 29th, 2021 by Ann-Marie Roche in Pharma R&D
One of the frustrations of our Big Data era is that, despite the existence of an ever-growing wealth of valuable data, this data is often stuck in different silos. This lack of accessibility makes it hard to get the most out of data that has the potential to be extremely useful.
(more…)Elsevier to Work with Heel for Mechanism-based Drug Action Discovery
Posted on January 6th, 2021 by Thea Howe in Pharma R&D
Elsevier, the data analytics business specialized in science and health, and Heel, a pharmaceutical company specialized in developing and manufacturing medicines made from natural ingredients, have recently completed a series of research projects with a focus on improving exploratory preclinical studies.
(more…)
